Mary Tagliaferri - 11 Jun 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Reporting relationship: Director
Issuer ticker: YMAB
Reported as of: 11 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2024, 21:02:27 UTC
Prior SEC filing: 14 Mar 2024
Next SEC filing: 24 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ John LaRocca, Attorney-in-Fact

Key filing fact

Mary Tagliaferri filed Form 4 for Y-mAbs Therapeutics, Inc. (YMAB) on 13 Jun 2024.

Key facts

This page summarizes Mary Tagliaferri's Form 4 filing for Y-mAbs Therapeutics, Inc. (YMAB).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2024, 21:02.

Change

Previous filing in this sequence was filed on 14 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

YMAB transaction

Common Stock

Award

Transaction value: $0
Shares: +3,495
Change %: +75%
Price: $0.000000
Shares after: 8,155
Date: 11 Jun 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

YMAB transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +14,545
Change %
Price: $0.000000
Shares after: 14,545
Date: 11 Jun 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 14,545
Exercise price: $12.01
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock on the vesting date of the RSUs. The RSUs vest in full on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the Issuer's annual meeting of stockholders held in 2025, subject to the Reporting Person's continued service to the Issuer on the vesting date.

Footnote F2

Stock options granted to the Reporting Person pursuant to the Issuer's 2018 Equity Incentive Plan.

Footnote F3

The stock options vest in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer on each vesting date, and are exercisable immediately upon vesting.